Literature DB >> 21700646

In-patient versus out-patient withdrawal programmes for medication overuse headache: a 2-year randomized trial.

C Créac'h1, P Frappe, M Cancade, B Laurent, R Peyron, G Demarquay, M Navez.   

Abstract

BACKGROUND: Medication-overuse headache (MOH) management usually includes a medication withdrawal. The choice of withdrawal modalities remains a matter of debate.
METHODS: We compared the efficacy of in-patient versus out-patient withdrawal programmes in 82 consecutive patients with MOH in an open-label prospective randomized trial. The main outcome measure was the reduction in number of headache days after 2 months and after 2 years. The responders were defined as patients who had reverted to episodic headaches and to an intake of acute treatments for headache less than 10 days per month.
RESULTS: Seventy-one patients had a complete drug withdrawal (n = 36 in the out-patient group; n = 35 in the in-patient group). The reduction of headache frequency and subjective improvement did not differ between groups. The long-term responder rate was similar in the out- and in- patient groups (44% and 44%; p = 0.810). The only predictive factor of a bad outcome 2 years after withdrawal was an initial consumption of more than 150 units of acute treatments for headache per month (OR = 3.1; 95% confidence interval 1.1-9.3; p = 0.044).
CONCLUSION: Given that we did not observe any difference in efficacy between the in- and out-patient withdrawals, we would recommend out-patient withdrawal in the first instance for patients with uncomplicated MOH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700646     DOI: 10.1177/0333102411412088

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  11 in total

Review 1.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

2.  [Preventing and treating medication overuse headache].

Authors:  K B Alstadhaug; H K Ofte; E S Kristoffersen
Journal:  Schmerz       Date:  2018-06       Impact factor: 1.107

3.  [Classification and therapy of medication-overuse headache: impact of the third edition of the International Classification of Headache Disorders].

Authors:  H Göbel; K Heinze-Kuhn; I Petersen; C Göbel; A Göbel; A Heinze
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 4.  Medication overuse headache: history, features, prevention and management strategies.

Authors:  Joel R Saper; Arnaldo Neves Da Silva
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

Review 5.  Medication-overuse headache: a review.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  J Pain Res       Date:  2014-06-26       Impact factor: 3.133

6.  OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.

Authors:  Danièle Ranoux; Gaelle Martiné; Gaëlle Espagne-Dubreuilh; Marlène Amilhaud-Bordier; François Caire; Laurent Magy
Journal:  J Headache Pain       Date:  2017-07-21       Impact factor: 7.277

7.  Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial.

Authors:  Paolo Rossi; Jessica Veronica Faroni; Cristina Tassorelli; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2013-02-08       Impact factor: 7.277

8.  Biofeedback in the prophylactic treatment of medication overuse headache: a pilot randomized controlled trial.

Authors:  Marialuisa Rausa; Daniela Palomba; Sabina Cevoli; Luana Lazzerini; Elisa Sancisi; Pietro Cortelli; Giulia Pierangeli
Journal:  J Headache Pain       Date:  2016-09-22       Impact factor: 7.277

9.  Preventing and treating medication overuse headache.

Authors:  Karl B Alstadhaug; Hilde K Ofte; Espen S Kristoffersen
Journal:  Pain Rep       Date:  2017-07-26

Review 10.  Medication-overuse headache: a widely recognized entity amidst ongoing debate.

Authors:  Nicolas Vandenbussche; Domenico Laterza; Marco Lisicki; Joseph Lloyd; Chiara Lupi; Hannes Tischler; Kati Toom; Fenne Vandervorst; Simone Quintana; Koen Paemeleire; Zaza Katsarava
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.